Topoisomerase I and II Inhibitors Control Caspase-2 Pre-Messenger RNA Splicing in Human Cells

Molecular Cancer Research

Volumn 2, Issue 1, 2004, Pages 53-61

  Solier, Stéphanie ^a,b   Lansiaux, Amélie ^c   Logette, Emmanuelle ^a   Wu, Jane ^d   Soret, Johann ^e   Tazi, Jamal ^e   Bailly, Christian ^c   Desoche, Lydie ^a   Solary, Eric ^a   Corcos, Laurent ^a  

^a INSERM   (France)

^b HÔPITAL DU BOCAGE   (France)

^c Institut de Recherche sur le Cancer de Lille   (France)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ALKYLATING AGENT; AMSACRINE; BN 80765; BN 80927; CAMPTOTHECIN; CARBAZOLE DERIVATIVE; CASPASE 2; CASPASE 2L; CASPASE 2S; CIS ACTING ELEMENT; CISPLATIN; CYTOTOXIC AGENT; DIFLOMOTECAN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCOSYLINDOLOCARBAZOLE DERIVATIVE; HOMOCAMPTOTHECIN DERIVATIVE; INTERCALATING AGENT; MELPHALAN; MESSENGER RNA PRECURSOR; MITOXANTRONE; TOPOISOMERASE I INHIBITOR; TOPOISOMERASE II INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE;

ALTERNATIVE RNA SPLICING; ARTICLE; CELL DEATH; CONTROLLED STUDY; EXON; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRON; LEUKEMIA CELL LINE; PRIORITY JOURNAL; RNA SPLICING;

ALTERNATIVE SPLICING; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BLOTTING, WESTERN; CASPASE 2; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; CYSTEINE ENDOPEPTIDASES; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; ENZYME INHIBITORS; GENETIC VECTORS; HL-60 CELLS; HUMANS; NUCLEIC ACID SYNTHESIS INHIBITORS; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; TRANSFECTION; U937 CELLS;

MURINAE;

EID: 0842304139     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Modrek, B. and Lee, C. A genomic view of alternative splicing. Nat. Genet., 30: 13-19, 2002.
2. Caceres, J. F. and Komblihtt, A. R. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet., 18: 186-193, 2002.
3. Zhou, Z., Licklider, L. J., Gygi, S. P., and Reed, R. Comprehensive proteomic analysis of the human spliceosome. Nature, 419: 182-185, 2002.
4. Manley, J. L. and Tacke, R. SR proteins and splicing control. Genes Dev., 10: 1569-1579, 1996.
5. Graveley, B. R. Sorting out the complexity of SR protein functions. RNA, 6: 1197-1211, 2000.
6. Tacke, R. and Manley J. L. Determinants of SR protein specificity. Curr. Opin. Cell Biol., 11: 358-362, 1999.
7. Cartegni, L., Chew, S. L., and Krainer, A. R. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet., 3: 285-298, 2002.
8. Wu, J. Y. and Maniatis, T. Specific interactions between proteins implicated in splice site selection and regulated alternative splicing. Cell, 75: 1061-1070, 1993.
9. Amrein, H., Hedley, M. L., and Maniatis, T. The role of specific protein-RNA and protein-protein interactions in positive and negative control of pre-mRNA splicing by Transformer 2. Cell, 76: 735-746, 1994.
10. Maniatis, T. and Tasic, B. Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature, 418: 236-243, 2002.
11. Tazi, J., Rossi, F., Labourier, E., Gallouzi, I., Brunel, C., and Antoine, E. DNA topoisomemse I: customs officer at the border between DNA and RNA worlds? J. Mol. Med., 75: 786-800, 1997.
12. Pilch, B., Allemand, E., Facompre, M., Bailly, C., Riou, J., F., Soret, J., and Tazi, J. Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506. Cancer Res., 61: 6876-6884, 2001.
13. Jiang, Z. H. and Wu, J. Y. Alternative splicing and programmed cell death. Proc. Soc. Exp. Biol. Med., 220: 64-72, 1999.
14. Paroni, G., Henderson, C., Schneider, C., and Brancolini, C. Caspase-2-induced apoptosis is dependent on caspase-9, but its processing during UV- or tumor necrosis factor-dependent cell death requires caspase-3. J. Biol. Chem., 276: 21907-21915, 2001.
15. Lassus, P., Opitz-Araya, X., and Lazebnik, Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science, 297: 1352-1354, 2002.
16. Wang, L., Miura, M., Bergeron, L., Zhu, H., and Yuan, J. Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell, 78: 739-750, 1994.
17. Droin, N., Rebe, C., Bichat, F., Hammann, A., Bertrand, R., and Solary E. Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalization. Oncogene, 20: 260-269, 2001.
18. Cote, J., Dupuis, S., Jiang, Z., and Wu, J. Y. Caspase-2 pre-mRNA alternative splicing: identification of an intronic element containing a decoy 3′ acceptor site. Proc. Natl. Acad. Sci. USA, 98: 938-943, 2001.
19. Jiang, Z. H., Zhang, W. J., Rao, Y., and Wu, J. Y. Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. Proc. Natl. Acad. Sci. USA, 95: 9155-9160, 1998.
20. Cote, J., Dupuis, S., and Wu, J. Y. Polypyrimidine track-binding protein binding downstream of caspase-2 alternative exon 9 represses its inclusion. J. Biol. Chem., 276: 8535-8543, 2001.
21. Wotawa, A., Solier, S., Logette, E., Solary, E., and Corcos, L. Differential influence of etoposide on two caspase-2 mRNA isoforms in leukemic cells. Cancer Lett., 185: 181-189, 2002.
22. Urasaki, Y., Laco, G., Takebayashi, Y., Bailly, C., Kohlhagen, G., and Pommier, Y. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. Cancer Res., 61: 504-508, 2001.
23. Pollack, S., Young, L., Bilsland, J., Wilkie, N., Ellis, S., Hefti, F., Broughton, H., and Harper, S. The staurosporine-like compound L-753,000 (NB-506) potentiates the neurotrophic effects of neurotrophin-3 by acting selectively at the TrkA receptor. Mol. Pharmacol., 56: 185-195, 1999.
24. Fujimori, A., Harker, W. G., Kohlhagen, G., Hoki, Y., and Pommier, Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res., 55: 1339-1346, 1995.
25. Rossi, F., Labourier, E., Forne, T., Divita, G., Derancourt, J., Riou, J. F., Antoine, E., Cathala, G., Brunel, C., and Tazi, J. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature, 381: 80-82, 1996.
26. Bailly, C. Targeting DNA and topoisomerase I with indolocarbazole antitumor agents. In: M. Demeunynck, C. Bailly, and W. D. Wilson, Small Molecule DNA and RNA Binders, Vol. 2, pp. 538-575. Weinheim, Germany: Wiley-VCH, 2003.
27. Wang, J. C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell Biol., 3: 430-440, 2002.
28. Mao, Y., Mehl, I. R., and Muller, M. T. Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status. Proc. Natl. Acad. Sci. USA, 99: 1235-1240, 2002.
29. Shaiu, W. L. and Hsieh, T. S. Targeting to transcriptionally active loci by the hydrophilic N-terminal domain of Drosophila DNA topoisomerase I. Mol. Cell. Biol., 18: 4358-4367, 1998.
30. Cowell, I. G., Okorokov, A. L., Cutts, S. A., Padget, K., Bell, M., Milner, J., and Austin, C. A. Human topoisomerase IIα and IIβ interact with the C-terminal region of p53. Exp. Cell Res., 255: 86-94, 2000.
31. Andersen, F. F., Tange, T. O., Sinnathamby, T., Olesen, J. R., Andersen, K. E., Westergaard, O., Kjems, J., and Knudsen, B. R. The RNA splicing factor ASF/ SF2 inhibits human topoisomerase I mediated DNA relaxation. J. Mol. Biol., 322: 677-686, 2002.
32. Plo, I., Hernandez, H., Kohlhagen, G., Lautier, D., Pommier, Y., and Laurent, G. Overexpression of the atypical protein kinase C ζ reduces topoisomerase II catalytic activity, cleavable complexes formation, and drug-induced cytotoxicity in monocytic U937 leukemia cells. J. Biol. Chem., 277: 31407-31415, 2002.
33. Solary, E., Droin, N., Bettaieb, A., Corcos, L., Dimanche-Boitrel, M. T., and Garrido, C. Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia, 14: 1833-1849, 2000.
34. Wright, M. M. and McMaster, C. R. Phospholipid synthesis, diacylglycerol compartmentation, and apoptosis. Biol. Res., 35: 223-229, 2002.
35. Bottero, V., Busuttil, V., Loubat, A., Magne, N., Fischel, J. L., Milano, G., and Peyron, J. F. Activation of nuclear factor κB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res., 61: 7785-7791, 2001.
36. Budman, D. R., Calabro, A., and Kreis, W. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anticancer Drugs, 9: 697-702, 1998.
37. Guichard, S., Amould, S., Hennebelle, I., Bugat, R., and Canal, P. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anticancer Drugs, 12: 741-751, 2001.
38. Soret, J. A., Gabut, M., Dupon, C., Kohlhagen, G., Stévenin, J., Pommier, Y. and Tazi, L.J. Altered serine/arginine-rich protein phosphorylation and exonic enhancer-dependent splicing in mammalian cells lacking topoisomerase I. Cancer Res., 63: 8203-8211, 2003.
39. Sordet, O., Khan, Q. A., Kohn, K. W., and Pommier, Y. Apoptosis induced by topoisomerase inhibitors. Curr. Med. Chem. Anti-Canc. Agents, 3: 271-290, 2003.
40. Atsumi, R., Okazaki, O., and Hakusui, H. Pharmacokinetics of SN-38 [(+)-(4S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3′,4′:6,7] -indolizino[1,2-b]quinoline-3,14(4H,12H)-21 dione], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats. Biol. Pharm. Bull., 18: 1114-1119, 1995.
41. Bailly, C. Homocamptothecins: potent topoisomerase 1 inhibitors and promising anticancer drugs. Crit. Rev. Oncol. Hematol., 45, 91-108, 2003.
42. Long, B. H., Rose, W. C., Vyas, D. M., Matson, J. A., and Forenza, S. Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Curr. Med. Chem. Anti-Canc. Agents, 2: 255-266, 2002.
43. Palumbo, M., Gatto, B., Moro, S., Sissi, C., and Zagotto, G. Sequence-specific interactions of drugs interfering with the topoisomerase-DNA cleavage complex. Biochim. Biophys. Acta, 1587: 145-154, 2002.
44. Binaschi, M., Bigioni, M., Cipollone, A., Rossi, C., Goso, C., Maggi, C. A., Capranico, G., and Animati, F. Anthracyclines: selected new developments. Curr. Med. Chem. Anti-Canc. Agents, 1: 113-130, 2001.
45. Nitiss, J. L. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage. Curr. Opin. Investig. Drugs, 3: 1512-1516, 2002.
46. Fortune, J. M., Velea, L., Graves, D. E., Utsugi, T., Yamada, Y., and Osheroff, N. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomemse catalytic inhibition. Biochemistry, 38: 15580-15586, 1999.
47. Hande, K. R. Etoposide: four decades of development of a topoisomerase II inhibiton. Eur. J. Cancer, 34: 1514-1521, 1998.
48. Longley, D. B., Harkin, D. P., and Johnston, P. G. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer, 3: 330-338, 2003.
49. Fuertes, M. A., Castilla, J., Alonso, C., and Perez, J. M. Novel concepts in the development of platinum antitumor drugs. Curr. Med. Chem. Anti-Canc. Agents, 2: 539-551, 2002.
50. Rajkumar, S. V., Gertz, M. A., Kyle, R. A., and Greipp, P. R. Current therapy for multiple myeloma. Mayo Clin. Proc., 77: 813-822, 2002.
51. Duflos, A., Kruczynski, A., and Barret, J. M. Novel aspects of natural and modified Vinca alkaloids. Curr. Med. Chem. Anti-Canc. Agents, 2: 55-70, 2002.